Table 1 Patient characteristics
From: Impact of smoking amount on clinicopathological features and survival in non-small cell lung cancer
GROUP | High (N = 233) | Low (N = 206) | p |
|---|---|---|---|
Age | 67.3 ± 6.2 | 67.1 ± 6.4 | 0.670 |
Sex | Â | Â | 0.000 |
 Male | 226 (97.0%) | 116 (56.3%) |  |
 Female | 7 (3.0%) | 90 (43.7%) |  |
BMI | 22.6 ± 3.1 | 23.4 ± 2.8 | 0.003 |
Symptoms at presentation | 143 (61.4%) | 96 (46.6%) | 0.003 |
Smoking status | Â | Â | 0.000 |
 Current | 133 (57.1%) | 33 (16.0%) |  |
 Ex + Never | 100 (42.9%) | 173 (84.0%) |  |
Pack-years | 55.0 ± 19.5 | 11.2 ± 14.1 | 0.000 |
Abstinence duration | 5.3 ± 4.8 | 15.1 ± 12.1 | 0.000 |
Comorbidities | |||
 Tuberculosis | 46 (19.7%) | 31 (15.0%) | 0.244 |
 Diabetes mellitus | 77 (33.0%) | 52 (25.2%) | 0.092 |
 Heart disease | 38 (16.3%) | 25 (12.1%) | 0.268 |
 Other cancer history | 32 (13.7%) | 30 (14.6%) | 0.911 |
Cancer | |||
 Stomach cancer | 5 (2.1%) | 6 (2.9%) | 0.836 |
 Colon cancer | 4 (1.7%) | 6 (2.9%) | 0.605 |
 Thyroid cancer | 2 (0.9%) | 6 (2.9%) | 0.212 |
 Hepatoma cancer | 4 (1.7%) | 3 (1.5%) | 1 |
 Renal cell cancer | 4 (1.7%) | 2 (1.0%) | 0.795 |
 Bladder cancer | 3 (1.3%) | 2 (1.0%) | 1 |
 Pancreatic cancer | 1 (0.4%) | 1 (0.5%) | 1 |
 Uterine cervix cancer | 1 (0.4%) | 2 (1.0%) | 0.915 |
 Biliary cancer | 0 (0.0%) | 1 (0.5%) | 0.951 |
 Ovary cancer | 0 (0.0%) | 1 (0.5%) | 0.951 |
 Prostate cancer | 2 (0.9%) | 0 (0.0%) | 0.533 |
 Breast cancer | 1 (0.4%) | 1 (0.5%) | 1 |
 Rectal cancer | 3 (1.3%) | 1 (0.5%) | 0.704 |
 other cancer | 6 (2.6%) | 4 (1.9%) | 0.902 |
Clinical Stage | Â | Â | 0.000 |
 I/II | 69 (29.6%) | 98 (47.6%) |  |
 III | 86 (36.9%) | 25 (12.1%) |  |
 IV | 78 (33.5%) | 83 (40.3%) |  |
Histology | Â | Â | 0.000 |
 Adeno | 94 (40.3%) | 156 (75.7%) |  |
 Squamous | 131 (56.2%) | 39 (18.9%) |  |
 Large | 1 (0.4%) | 0 (0.0%) |  |
 Other | 7 (3.0%) | 11 (5.3%) |  |
Differentiation | Â | Â | 0.001 |
 Well | 13 (5.6%) | 34 (16.5%) |  |
 Moderate | 87 (37.3%) | 84 (40.8%) |  |
 Poorly | 65 (27.9%) | 40 (19.4%) |  |
 Unknown | 68 (29.2%) | 48 (23.3%) |  |
Driver mutation | |||
 EGFR | 22 (11.8%) | 72 (39.1%) | 0.000 |
 19Del | 9 (4.8%) | 39 (21.2%) | 0.000 |
 L858R | 9 (4.8%) | 25 (13.6%) | 0.006 |
 Others | 4 (2.2%) | 8 (4.3%) | 0.368 |
 ALK | 7 (3.9%) | 5 (2.8%) | 0.769 |
Pulmonary function | |||
 FVC(%) | 81.7 ± 18.0 | 87.9 ± 20.7 | 0.001 |
 FEV1(%) | 72.9 ± 21.4 | 88.5 ± 22.5 | 0.000 |
 FEV1/FVC | 0.63 ± 0.13 | 0.72 ± 0.10 | 0.000 |
 DLCO(%) | 74.3 ± 20.8 | 82.7 ± 20.6 | 0.000 |
Treatment | |||
 Surgery | 87 (37.3%) | 101 (49.0%) | 0.018 |
 Chemotherapy | 156 (67.0%) | 131 (63.6%) | 0.523 |
 Mean cycle | 3.6 ± 2.0 | 4.0 ± 2.3 | 0.139 |
 Mean line | 1.5 ± 0.5 | 1.4 ± 0.5 | 0.059 |
 Radiation | 60 (25.8%) | 52 (25.2%) | 0.990 |